FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’
The FDA has refused to consider Moderna's application for a new flu vaccine based on mRNA technology. The agency claims the application was rejected due to a lack of "adequate and well-controlled" clinical trials. However, experts argue that the FDA is simply "coming up with reasons" and that this decision is part of an "anti-vaccine agenda." They assert that the FDA's move is already having a chilling effect on the development of new vaccines. The FDA official has described Moderna's clinical trial as a "brazen failure," suggesting that the agency's decision is based on concerns over the trial's quality and effectiveness. This decision has sparked debate among healthcare professionals and vaccine experts, who are questioning the FDA's rationale and the potential impact on future vaccine development.
Source: For the complete article, please visit the original source link below.
